The vaccine market is expected to reach approximately $35 billion by 2014 and currently there is a large number of companies and research institutions that are entering the field with novel concepts and approaches.
In this section of biohive.net, vaccine candidates and technologies (preclinical and clinical stage) are being critically evaluated in terms of their advantages and disadvantages.
In this section of biohive.net, vaccine candidates and technologies (preclinical and clinical stage) are being critically evaluated in terms of their advantages and disadvantages.
If you would like to suggest any vaccine-related articles, news or developments, or if you want to see a particular vaccine candidate or approach being presented and analyzed by BioHive, please send an email to info@biohive.net.